voltage-gated calcium channel drug
Evidence from:
primary |
all sources
Related entities (6)
Mentioned in (15)
Papers in which this entity is mentioned.
- Mapping genomic loci implicates genes and synaptic biology in schizophrenia. (2022)
- Transient Potassium Channels: Therapeutic Targets for Brain Disorders. (2019)
- Hippocampal deficits in neurodevelopmental disorders. (2019)
- Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. (2018)
- Cross-disorder risk gene CACNA1C differentially modulates susceptibility to psychiatric disorders during development and adulthood. (2018)
- Neuronal substrates and functional consequences of prenatal cannabis exposure. (2014)
- Gabapentin treatment for alcohol dependence: a randomized clinical trial. (2014)
- Glycine receptors and brain development. (2013)
- Synaptic effects induced by alcohol. (2013)
- Early exposure to alcohol leads to permanent impairment of dendritic excitability in neocortical pyramidal neurons. (2012)
- How inhibition shapes cortical activity. (2011)
- Low concentrations of alcohol inhibit BDNF-dependent GABAergic plasticity via L-type Ca2+ channel inhibition in developing CA3 hippocampal pyramidal neurons. (2010)
- Neurotoxic effects and biomarkers of lead exposure: a review. (2009)
- Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. (2009)
- Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons. (2008)
Merged raw entities (4)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| voltage-gated calcium channels | drug | 8 | 9 |
| voltage-gated calcium channel | drug | 6 | 6 |
| vgcc | drug | 4 | 5 |
| voltage‑gated ca2+ channel | drug | — | — |